Lanraplenib succinate

Overview

Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor ( IC 50 =9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Rheumatoid Arthritis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Syk

Product Information

• Catalog No.: HY-109091B
• CAS No.: 1800047-00-0
• Molecular Formula: C23H25N9O.3/2C4H6O4
• Molecular Weight: 620.64
• Purity: 98.09%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.08 mg/mL (3.35 mM); Clear solution
• Availability: In-stock

Source

Original product source